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Background
The molecular etiology of inflammatory bowel diseases
(IBD) is largely unknown.
Methods
We performed genetic linkage analysis and candidate
gene sequencing in two unrelated consanguineous
families with children affected by early-onset IBD. We
screened six additional patients for mutations in two
candidate genes and carried out functional assays in
patients’ peripheral blood mononuclear cells. We treated
one patient with an allogeneic hematopoietic stem cell
transplant (HSCT).
Results
We identified three distinct homozygous mutations in
the genes IL10RA and IL10RB, encoding the IL10R1 and
IL10R2 proteins, respectively (which form a heteromer
to make up the interleukin-10 receptor) in four of nine
patients with early-onset colitis. The mutations abrogate
IL10-induced signaling, as demonstrated by deficient
STAT3 phosphorylation upon IL10 stimulation. Consis-
tent with this observation is the increased secretion of
TNFa and other proinflammatory cytokines from per-
ipheral blood mononuclear cells from IL10R-deficient
patients, suggesting that IL10-dependent “negative feed-
back” regulation is disrupted in these cells. One patient
was successfully treated by an allogeneic HSCT.
Conclusions
Mutations in genes encoding the IL10R subunit proteins
cause human enterocolitis, involving hyperinflammatory
immune responses in the intestine. Allogeneic HSCT
may offer a cure for IL10 receptor deficiency.
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